Isoxsuprine Uses, Dosage, Side Effects & Benefits | DrugsAtlas
Authoritative Clinical Reference
DRUG NAME: Isoxsuprine
Therapeutic Class: Vasodilator
Subclass: β2-Adrenergic Agonist
Speciality: Cardiology
Schedule (India): Schedule H
Route(s): Oral, Intramuscular, Intravenous (slow)
Formulations Available in India:
• Tablets: 10 mg, 20 mg
• Injection: 5 mg/mL (1 mL ampoule)
• Tablets: 10 mg, 20 mg
• Injection: 5 mg/mL (1 mL ampoule)
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Peripheral Vascular Disease
(Buerger’s disease, Raynaud’s phenomenon, arteriosclerosis obliterans, cerebrovascular insufficiency)
(Buerger’s disease, Raynaud’s phenomenon, arteriosclerosis obliterans, cerebrovascular insufficiency)
Oral Administration:
| Parameter | Recommendation |
| Starting dose | 10 mg three times daily |
| Titration | Increase to 20 mg three times daily after 1–2 weeks if tolerated |
| Usual maintenance dose | 10–20 mg three times daily (30–60 mg/day) |
| Maximum dose | 80 mg/day in divided doses |
Intramuscular Administration (acute symptoms or when oral not feasible):
| Parameter | Recommendation |
| Starting dose | 5 mg IM |
| Titration | Based on clinical response |
| Usual maintenance dose | 5 mg IM three to four times daily |
| Maximum dose | 20 mg/day IM |
Clinical Notes:
- Therapeutic response in PVD may take 2–4 weeks to manifest
- IM route reserved for short-term use due to local tissue irritation
- Combine with smoking cessation, exercise therapy, and risk factor management
2. Threatened Preterm Labour (Tocolysis)
Specialist use only — Obstetric supervision mandatory
Specialist use only — Obstetric supervision mandatory
Intravenous Administration (acute tocolysis):
| Parameter | Recommendation |
| Starting dose | 5–10 mg diluted in 10 mL normal saline, given over 5–10 minutes |
| Titration | Repeat dose after 4–6 hours if uterine contractions persist |
| Usual maintenance dose | As per clinical response |
| Maximum dose | Not to exceed 40 mg/day IV |
Intramuscular Administration:
| Parameter | Recommendation |
| Starting dose | 5 mg IM |
| Titration | Based on uterine activity |
| Usual maintenance dose | 5 mg IM every 6 hours |
| Maximum dose | 20 mg/day; limit duration to 2–3 days |
Oral Administration (maintenance after acute phase):
| Parameter | Recommendation |
| Starting dose | 10 mg three times daily |
| Titration | Increase to 20 mg three times daily if needed |
| Usual maintenance dose | 10–20 mg three times daily |
| Maximum dose | 60 mg/day; duration generally limited to 7 days |
Clinical Notes:
- Safer tocolytic alternatives available (nifedipine preferred in Indian practice)
- Reserved for cases where first-line tocolytics are contraindicated or unavailable
- Continuous maternal and fetal monitoring mandatory during parenteral use
Secondary Indications – Adults (Off-label)
| Indication | Dose | Duration | Evidence Basis |
| Cervical ripening (late pregnancy) — OFF-LABEL | 20 mg orally three times daily | 3–5 days before expected delivery | Indian obstetric specialist practice; limited evidence |
Note: Specialist only — practice varies among obstetricians; not routine recommendation
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not applicable. Isoxsuprine is not routinely indicated in paediatric populations.
Secondary Indications – Paediatrics (Off-label)
Not applicable. Peripheral vascular disease is uncommon in children.
| Age Group | Recommendation |
| Below 12 years | NOT RECOMMENDED — insufficient safety and efficacy data |
| 12–18 years | May be considered under specialist supervision only; dose as per adult guidelines with caution |
Safety Monitoring (if used in adolescents):
- Heart rate and blood pressure monitoring
- Assessment for tremor, palpitations, dizziness
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| Mild to moderate impairment | No specific dose adjustment required |
| Severe impairment (eGFR <30 mL/min) | Use with caution; limited pharmacokinetic data available |
| Haemodialysis | Avoid IV use unless strongly indicated; not significantly dialyzable |
HEPATIC ADJUSTMENT
| Hepatic Function | Recommendation |
| Mild impairment (Child-Pugh A) | No dose adjustment required |
| Moderate impairment (Child-Pugh B) | Use with caution; monitor for hypotensive effects |
| Severe impairment (Child-Pugh C) | Avoid use — risk of drug accumulation and severe hypotension |
CONTRAINDICATIONS
• Known hypersensitivity to isoxsuprine or any formulation component
• Active arterial bleeding
• Recent cerebral haemorrhage or haemorrhagic stroke
• Severe hypotension (systolic BP <90 mmHg)
• Significant cardiac arrhythmias or obstructive cardiac conditions
• Uncontrolled hyperthyroidism
• First trimester of pregnancy (for obstetric indications)
• Immediate postpartum period (increased bleeding risk)
• Active arterial bleeding
• Recent cerebral haemorrhage or haemorrhagic stroke
• Severe hypotension (systolic BP <90 mmHg)
• Significant cardiac arrhythmias or obstructive cardiac conditions
• Uncontrolled hyperthyroidism
• First trimester of pregnancy (for obstetric indications)
• Immediate postpartum period (increased bleeding risk)
CAUTIONS
• Ischaemic heart disease — risk of reflex tachycardia and angina
• Diabetes mellitus — may affect glycaemic control
• Narrow-angle glaucoma — β2-agonist activity may elevate intraocular pressure
• History of cerebrovascular disease
• Concurrent use of other sympathomimetics or tocolytics
• Elderly patients — increased susceptibility to hypotension and falls
• Repeated IM administration — risk of local tissue irritation and sterile abscess
• Diabetes mellitus — may affect glycaemic control
• Narrow-angle glaucoma — β2-agonist activity may elevate intraocular pressure
• History of cerebrovascular disease
• Concurrent use of other sympathomimetics or tocolytics
• Elderly patients — increased susceptibility to hypotension and falls
• Repeated IM administration — risk of local tissue irritation and sterile abscess
PREGNANCY
| Parameter | Recommendation |
| Overall safety | Limited human data; use only when benefit clearly outweighs risk |
| First trimester | Contraindicated for obstetric indications |
| Second/Third trimester | May be used for tocolysis under obstetric supervision |
| Preferred alternatives | Nifedipine (first-line tocolytic); Atosiban (if available); Progesterone (maintenance) |
| Maternal monitoring | Blood pressure, pulse rate, fluid balance, uterine activity |
| Fetal monitoring | Continuous fetal heart rate monitoring during parenteral use |
LACTATION
| Parameter | Information |
| Compatibility | Limited data; use with caution |
| Expected milk levels | Likely low; minimal systemic absorption |
| Preferred alternatives | Nifedipine if tocolysis needed in breastfeeding mother |
| Infant monitoring | Irritability, tachycardia, feeding difficulties |
| Recommendation | Avoid during high-dose IV therapy; oral use acceptable with monitoring |
ELDERLY
| Parameter | Recommendation |
| Starting dose | 10 mg once or twice daily (lower end of range) |
| Titration | Slow — increase only after 1–2 weeks if tolerated |
| Special risks | Postural hypotension, falls, dizziness, reflex tachycardia, confusion |
| Route preference | Oral preferred; avoid IM due to muscle fragility and pain |
| Monitoring | Blood pressure (supine and standing), heart rate, symptoms of orthostasis |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Mechanism/Effect | Recommendation |
| MAO inhibitors | Potentiation of adrenergic effects; risk of hypertensive crisis | Avoid concurrent use |
| Non-selective beta-blockers | Antagonism of vasodilatory effect | Avoid combination; therapeutic failure likely |
| Other sympathomimetics (salbutamol, terbutaline) | Additive cardiovascular stimulation | Avoid concurrent use; risk of severe tachycardia |
| Ergot alkaloids | Antagonistic vascular effects | Avoid concurrent use |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Recommendation |
| Antihypertensives (CCBs, ACE inhibitors) | Additive hypotensive effect | Monitor blood pressure; adjust doses as needed |
| Loop/thiazide diuretics | Enhanced hypotension; potential electrolyte disturbance | Monitor BP and electrolytes |
| Antidiabetic agents | Possible interference with glycaemic control | Monitor blood glucose |
| General anaesthetics | Enhanced cardiovascular instability | Inform anaesthetist; perioperative monitoring |
| Digoxin | Potential for additive cardiac effects | Monitor heart rate and rhythm |
COMMON ADVERSE EFFECTS
• Headache
• Palpitations
• Tachycardia
• Dizziness
• Flushing
• Nausea
• Tremor
• Mild hypotension
• Injection site discomfort (IM route)
• Palpitations
• Tachycardia
• Dizziness
• Flushing
• Nausea
• Tremor
• Mild hypotension
• Injection site discomfort (IM route)
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Action |
| Tachyarrhythmias | Discontinue; ECG monitoring; supportive care |
| Severe hypotension | Discontinue IV infusion; fluid resuscitation; consider vasopressors |
| Angina / Myocardial ischaemia | Discontinue immediately; cardiac evaluation |
| Pulmonary oedema (with tocolysis) | Discontinue; diuretics; oxygen support |
| Hypersensitivity reactions (rash, bronchospasm) | Discontinue; antihistamines; supportive care |
| Confusion / CNS disturbance (elderly) | Dose reduction or discontinuation |
MONITORING REQUIREMENTS
Baseline:
• Blood pressure and heart rate
• Cardiovascular history and examination
• Blood glucose (in diabetics)
• Assessment of peripheral circulation (for PVD)
• Blood pressure and heart rate
• Cardiovascular history and examination
• Blood glucose (in diabetics)
• Assessment of peripheral circulation (for PVD)
After initiation / dose change:
• Blood pressure and pulse — daily during parenteral use; weekly during oral initiation
• Uterine activity and fetal heart rate (obstetric use)
• Fluid balance (during IV tocolysis)
• Symptoms of postural hypotension
• Blood pressure and pulse — daily during parenteral use; weekly during oral initiation
• Uterine activity and fetal heart rate (obstetric use)
• Fluid balance (during IV tocolysis)
• Symptoms of postural hypotension
Long-term:
• Periodic cardiovascular assessment
• Review of symptomatic improvement in PVD
• Blood glucose monitoring in diabetics
• Assessment of continued need for therapy
• Periodic cardiovascular assessment
• Review of symptomatic improvement in PVD
• Blood glucose monitoring in diabetics
• Assessment of continued need for therapy
BRANDS AVAILABLE IN INDIA
| Brand Name | Manufacturer | Formulation |
| Duvadilan | Abbott | Tablets 10 mg, 20 mg; Injection 5 mg/mL |
| Isoxilan | Various | Tablets 10 mg, 20 mg |
| Vasoprine | Various | Tablets 10 mg, 20 mg |
| Ausprin | Various | Tablets |
Note: Some brands available as FDCs — verify composition before prescribing
PRICE RANGE (INR)
| Formulation | Approximate Price |
| Tablet 10 mg | ₹2–5 per tablet |
| Tablet 20 mg | ₹3–7 per tablet |
| Injection 5 mg/mL (1 mL) | ₹8–15 per ampoule |
• NLEM status: Not listed
• NPPA price control: Not applicable
• Availability: Widely available in private pharmacies
• NPPA price control: Not applicable
• Availability: Widely available in private pharmacies
CLINICAL PEARLS
• Use in preterm labour has declined significantly — nifedipine is now preferred first-line tocolytic in Indian obstetric practice due to better safety profile
• Efficacy in peripheral vascular disease is modest — must be combined with smoking cessation, exercise rehabilitation, and cardiovascular risk factor control for meaningful outcomes
• Avoid repeated IM injections — risk of sterile abscess and local tissue necrosis; switch to oral route as soon as feasible
• Always assess cardiovascular status before initiation — even for peripheral vascular indications, cardiac risk is elevated in this population
• Counsel patients about postural hypotension — advise slow position changes, adequate hydration, and reporting dizziness promptly
• Not a rescue medication — therapeutic effect in PVD takes weeks; set appropriate patient expectations
TAGS
isoxsuprine; peripheral vascular disease; Buerger’s disease; Raynaud’s; vasodilator; tocolytic; β2-agonist; Duvadilan; preterm labour; pregnancy-caution
VERSION
RxIndia v1.0 — 28 Feb 2026
REFERENCES
• CDSCO-approved product inserts
• Indian Pharmacopoeia / National Formulary of India
• API Textbook of Medicine — Peripheral Arterial Disease chapter
• AIIMS Obstetric Protocols (Preterm Labour Management)
• NLEM 2022 (not listed — verified)
• Standard Indian prescribing practices in obstetrics and vascular medicine
• Indian Pharmacopoeia / National Formulary of India
• API Textbook of Medicine — Peripheral Arterial Disease chapter
• AIIMS Obstetric Protocols (Preterm Labour Management)
• NLEM 2022 (not listed — verified)
• Standard Indian prescribing practices in obstetrics and vascular medicine
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.